Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01460576 · ClinicalTrials.gov registry record
Improving Prematurity-Related Respiratory Outcomes at Vanderbilt
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 253
- Enrollment target
NCT01460576 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 253 participants.
The verdict
NCT01460576 has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 253 participants
- Enrollment target
Study Summary
The goal of IMPROV is to identify molecular mechanisms that contribute to lung injury and long-term breathing problems in preterm infants by investigating two interrelated biochemical pathways: the urea cycle-nitric oxide pathway and the glutathione pathway. The investigators hypothesize that prematurity-related limitations in the function of these important biochemical pathways contribute to respiratory disease risk over the first year of life.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 253 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01460576
The ClinicalTrials.gov registry entry for NCT01460576 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 253 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01460576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01460576 about?
NCT01460576 is a clinical study titled "Improving Prematurity-Related Respiratory Outcomes at Vanderbilt". The goal of IMPROV is to identify molecular mechanisms that contribute to lung injury and long-term breathing problems in preterm infants by investigating two interrelated biochemical pathways: the urea cycle-nitric oxide pathway and the glutathione pathway. The investigators hypothesize that premat...
What is the current status of trial NCT01460576?
This trial is currently completed. The enrollment target is 253 participants. The study started on 2011-09. Estimated completion is 2016-12.
Who is sponsoring clinical trial NCT01460576?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.